5-HT3 & Steroid Regimens
Serotonin antagonists and dexamethasone remain widely used building blocks in multimodal prophylaxis because of familiarity, broad availability and complementary mechanisms.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Treatment Type (Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Other Pharmacologic Treatments, Non-Pharmacologic Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies), and Regional Forecast, 2026-2034
The global postoperative nausea and vomiting (PONV) market was valued at USD 2.25 billion in 2025 and is estimated at USD 2.40 billion in 2026. The market is projected to reach USD 4.03 billion by 2034, representing a 6.7% CAGR during 2026–2034.
PONV is a common perioperative complication that can delay recovery, reduce patient satisfaction and increase the need for rescue medication or extended observation. Risk rises with patient, anesthetic and procedural factors, which is why contemporary management emphasizes preoperative risk assessment and multimodal prophylaxis rather than waiting to treat symptoms after they occur.
The treatment landscape spans 5-HT3 receptor antagonists, corticosteroids, dopamine antagonists, NK-1 receptor antagonists and selected non-pharmacologic interventions. Generic ondansetron and dexamethasone remain deeply embedded in perioperative pathways because of familiarity and low cost, while dedicated products such as intravenous amisulpride and injectable aprepitant broaden mechanism choice for higher-risk patients and rescue or prevention protocols.
Clinical guidance continues to evolve toward broader combination prophylaxis. The Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting were published in 2026, updating multidisciplinary recommendations on risk assessment, prevention and treatment. In parallel, current U.S. labels maintain dedicated PONV indications for BARHEMSYS and APONVIE, supporting a distinct branded segment within a market otherwise dominated by multi-source antiemetics.
Source: PONV review; Fifth Consensus Guidelines; DailyMed BARHEMSYS; Heron APONVIE.
The study covers pharmacologic and selected non-pharmacologic approaches used to prevent or treat postoperative nausea and vomiting. The report segments the market by treatment type and distribution channel, with hospital pharmacy demand reflecting direct perioperative use and other pharmacy channels supporting oral or post-discharge therapy.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Treatment Type | Serotonin Antagonists; Steroids; Dopamine Antagonists; NK-1 Receptor Antagonists; Other Pharmacologic Treatments; Non-Pharmacologic Treatment |
| By Distribution Channel | Hospital Pharmacies; Retail Pharmacies and Drug Stores; Online Pharmacies |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, GCC countries, South Africa and other major markets |
| Key Market Players | Heron Therapeutics, Inc.; Eagle Pharmaceuticals, Inc. / Acacia Pharma Ltd; Merck & Co., Inc.; Fresenius Kabi; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; Sandoz Group AG; Pfizer Inc.; Baxter International Inc.; Viatris Inc.; Dr. Reddy's Laboratories Ltd. |
The market includes antiemetic products and selected non-pharmacologic interventions used specifically for PONV prevention or treatment. For drugs with multiple indications, only utilization attributable to postoperative nausea and vomiting is included in the target-market revenue model.
Anesthesia drugs, analgesics, surgical devices and broader nausea-and-vomiting indications such as chemotherapy-induced nausea and vomiting are outside the core PONV market unless they directly influence perioperative risk or treatment choice.
Peer-reviewed evidence places PONV in 30% of surgical patients overall and up to 80% of high-risk patients. This burden creates predictable demand for prophylaxis in anesthesia protocols and rescue therapy in recovery units.
Modern guidance favors combining antiemetics that act through different receptors when patient risk is elevated. This increases the number of pharmacologic mechanisms used around a single procedure and supports continued demand across serotonin, steroid, dopamine and NK-1 classes rather than a single dominant molecule.
Ondansetron, dexamethasone and several other perioperative antiemetics are available from multiple generic suppliers. High utilization therefore does not translate directly into premium revenue, and branded products must demonstrate workflow, duration, rescue efficacy or mechanism advantages that justify higher acquisition costs.
Same-day surgery shortens direct clinical observation after discharge, increasing the importance of prevention that lasts beyond the immediate recovery room. Post-discharge nausea and vomiting is therefore commercially relevant to ambulatory settings, where symptom control can affect unplanned calls, delayed discharge and patient experience.
The 2026 Fifth Consensus Guidelines update multidisciplinary recommendations for PONV prevention and treatment. Their publication keeps risk stratification, combination prophylaxis and mechanism diversity at the center of perioperative practice, supporting continued demand across established and newer antiemetic classes.
BARHEMSYS is labeled for both prevention and treatment of PONV in adults, while APONVIE is indicated for prevention. These dedicated products create differentiated hospital-market opportunities even as low-cost generic antiemetics remain the volume backbone of routine care.
APONVIE is administered by a short intravenous infusion before anesthesia, while BARHEMSYS uses a single intravenous dose for prevention or treatment. Perioperative products that fit anesthesia workflow without complex preparation can gain preference where nursing and operating-room efficiency are important.
Enhanced recovery programs seek to reduce delayed discharge and improve postoperative function. Because nausea and vomiting can interfere with oral intake, mobilization and discharge readiness, PONV prevention is increasingly evaluated as part of broader recovery quality rather than as an isolated symptom-management issue.
PONV management combines patient risk assessment with pharmacologic mechanisms that target different emetic pathways. The commercial landscape therefore rewards broad availability of familiar generics while leaving room for differentiated agents in high-risk prophylaxis, rescue treatment and situations where additional receptor coverage is needed.
Serotonin antagonists and dexamethasone remain widely used building blocks in multimodal prophylaxis because of familiarity, broad availability and complementary mechanisms.
Aprepitant-based prevention provides a substance-P/NK-1 mechanism that can extend receptor coverage for patients at higher risk or where longer-duration protection is clinically desirable.
Intravenous amisulpride provides a dedicated dopamine-2 pathway for adult PONV prevention and treatment, broadening options when another class has already been used.
Treatment-type segmentation reflects the receptor mechanisms and non-pharmacologic approaches used across PONV prophylaxis and rescue care.
5-HT3 antagonists remain central to routine perioperative protocols because of extensive clinical familiarity, multiple formulations and broad generic availability. Their role is strongest as a base component of multimodal prophylaxis.
Dexamethasone is commonly paired with another antiemetic mechanism and supports high-volume use because of low acquisition cost and integration into multimodal protocols.
Dopamine-targeted antiemetics include older agents and dedicated intravenous amisulpride. Their value is strongest when additional receptor coverage or rescue after another prophylactic class is needed.
NK-1 antagonists such as aprepitant add longer-duration substance-P blockade and are commercially attractive in higher-risk prophylaxis, although acquisition cost is higher than many generic alternatives.
Antihistamines, anticholinergics and other agents remain useful in selected patients or combination regimens, but their roles vary by side-effect profile and local anesthesia practice.
Acupressure, acupuncture and related approaches can be used as adjuncts in selected settings. Their commercial role is smaller than pharmacologic prophylaxis but may expand where patients prefer drug-sparing strategies.
Distribution-channel analysis reflects where perioperative antiemetics are procured, administered and dispensed.
Hospital pharmacies lead because most prophylaxis and rescue treatment is ordered within surgical and anesthesia pathways. Intravenous products and immediate postoperative therapy are especially concentrated in institutional procurement.
Retail channels support oral antiemetics and post-discharge prescriptions, particularly for patients who require ongoing symptom control after leaving the surgical facility.
Online pharmacy growth is linked to home delivery and refill convenience for oral products, but direct perioperative administration keeps this channel secondary to institutional purchasing.
Regional analysis identifies where market value and growth are concentrated, then uses country-level evidence only where it materially explains demand, access, adoption or competitive conditions. The selected country signals are limited to markets with strong, commercially relevant evidence rather than attempting to profile every country in the geographic scope.
North America is the largest regional market, supported by high surgical throughput, standardized anesthesia protocols, broad availability of generic antiemetics and dedicated PONV products with U.S. regulatory approval. Hospital procurement and ambulatory surgery are both important, making reimbursement and operating-room workflow central to commercial performance.
Current U.S. labeling includes BARHEMSYS for adult PONV prevention and treatment and APONVIE for adult prevention. The presence of dedicated branded products alongside widely used generics creates a diverse perioperative antiemetic market in hospitals and ambulatory surgical settings.
Source: DailyMed / Heron Therapeutics.
Europe has mature anesthesia practice and high adoption of guideline-based multimodal prophylaxis. National procurement, generic substitution and hospital formularies create strong cost discipline, so premium products must demonstrate clinically meaningful advantages in duration, rescue effectiveness or workflow.
Asia-Pacific demand is supported by rising surgical capacity, expanding private hospital systems and increasing use of standardized anesthesia protocols. China, Japan, South Korea, India and Australia differ materially in reimbursement and hospital procurement, creating a mix of premium and cost-sensitive opportunities.
A 2025 national PONV guideline from the Chinese Society of Anesthesiology addressed 21 clinical issues and issued 35 recommendations. Standardized guidance can strengthen adoption of structured risk assessment and multimodal prevention across a large surgical market.
Latin American demand is centered on hospital surgical volume and cost-effective generic prophylaxis. Brazil, Mexico, Argentina and other larger markets offer growth as surgical capacity expands, but public procurement budgets and uneven access to newer branded antiemetics can constrain premium uptake.
Gulf health systems increasingly use modern anesthesia and ambulatory-surgery protocols, while many African markets remain constrained by surgical capacity, specialist staffing and medicine availability. Commercial strategies therefore need to balance premium hospital demand in the Gulf with essential-medicine affordability elsewhere.
PONV market access differs sharply by product type. Multi-source generics are inexpensive and commonly included in hospital formularies, while newer branded agents must secure pharmacy-and-therapeutics approval and demonstrate value within bundled surgical reimbursement.
Many perioperative medications are paid within broader surgical or facility reimbursement, increasing pressure on acquisition cost and encouraging hospital formulary standardization.
Heron states that APONVIE is separately reimbursed in physician offices under Medicare at ASP + 6%, while use in hospital outpatient departments, ASCs and inpatient procedures is packaged into the procedure payment.
Generic 5-HT3 antagonists, steroids and other antiemetics keep the baseline cost of multimodal prophylaxis low, requiring specialist products to compete on outcomes, duration or workflow.
Competition combines high-volume generic suppliers with specialist hospital-focused brands. Market position depends less on a single company share and more on formulary inclusion, anesthesia protocol placement, reliable injectable supply and differentiation in high-risk patients.
Heron Therapeutics competes with APONVIE for adult prevention, while Acacia Pharma, an Eagle Pharmaceuticals subsidiary, supplies BARHEMSYS for adult prevention and treatment.
Fresenius Kabi, Hikma, Teva, Sandoz, Pfizer, Baxter, Viatris and other suppliers participate across generic injectable or oral antiemetics used in perioperative practice.
Competitive advantage depends on receptor coverage, administration time, duration, rescue utility, acquisition cost and the ability to fit institutional multimodal protocols.
| Date | Development | Market Relevance |
|---|---|---|
| September 2022 | FDA approved APONVIE (aprepitant injectable emulsion) for prevention of PONV in adults. | Added a dedicated intravenous NK-1 option to perioperative prevention. |
| March 2023 | Heron Therapeutics commercially launched APONVIE in the United States. | Expanded commercial availability of a rapid-infusion aprepitant formulation for surgical settings. |
| November 2025 | The Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting became available online ahead of 2026 publication. | Updated multidisciplinary guidance on risk assessment, prophylaxis and treatment, reinforcing structured multimodal management. |
| June 2026 | DailyMed posted an updated BARHEMSYS label for adult PONV prevention and treatment. | Confirmed ongoing U.S. availability and current labeling for intravenous amisulpride in perioperative care. |
From 2026 through 2034, market growth is expected to come from rising surgical volumes, wider use of multimodal prophylaxis, expansion of ambulatory procedures and stronger attention to post-discharge recovery quality. Generic antiemetics will remain the volume foundation, while dedicated NK-1 and dopamine-targeted products can grow in higher-risk protocols where duration, rescue efficacy or alternative mechanisms justify premium hospital use.
2025 base-year value, 2026 estimate, 2034 forecast and the 2026–2034 growth trajectory.
Revenue and adoption analysis across the report’s defined product, application and customer dimensions.
Regional market positioning with selective priority-country evidence where it materially improves commercial interpretation.
Competitive positioning, portfolio breadth, launches, partnerships and market-access factors affecting supplier performance.
Demand mechanisms, adoption barriers, pricing, reimbursement, procurement and structural shifts affecting market growth.
Risk stratification, multimodal prophylaxis, rescue treatment, anesthesia workflow and the role of dedicated versus generic antiemetics.
The study combines top-down and bottom-up market modeling. Top-down analysis uses disease burden, treatment or procedure volumes, healthcare utilization, regulatory status, reimbursement structures and manufacturer disclosures to define the addressable market. Bottom-up analysis evaluates product portfolios, therapy or device categories, end-user demand, channel structure and supplier participation across major geographies.
Secondary research prioritizes regulators, government health agencies, professional guidelines, peer-reviewed publications, public procurement and reimbursement sources, and company annual reports or official product announcements. Primary research is used to test assumptions on adoption, pricing, purchasing behavior, substitution, treatment pathways and forecast drivers where applicable.
For medicines with broader indications, such as aprepitant or ondansetron, total product revenue is not assigned to PONV. The model allocates only the postoperative-use portion based on perioperative utilization, surgical demand, formulary patterns and other available evidence. CINV and unrelated nausea-and-vomiting indications remain outside the core market.
The market was valued at USD 2.25 billion in 2025, is estimated at USD 2.40 billion in 2026 and is projected to reach USD 4.03 billion by 2034, representing a 6.7% CAGR during 2026–2034.
Peer-reviewed evidence indicates PONV affects 30% of surgical patients overall and up to 80% of high-risk patients.
The report covers serotonin antagonists, steroids, dopamine antagonists, NK-1 receptor antagonists, other pharmacologic treatments and non-pharmacologic approaches.
North America is the largest regional market, supported by high surgical volumes, advanced anesthesia practice, extensive generic availability and dedicated PONV products.
BARHEMSYS is labeled for adult PONV prevention and treatment, while APONVIE is labeled for adult PONV prevention.
Growth is supported by surgical volume, multimodal prophylaxis, ambulatory surgery, enhanced-recovery pathways and demand for alternatives in patients at higher risk of nausea and vomiting.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.